Autonomix Medical, Inc. · NASDAQ:AMIX

Autonomix Medical — Investor Presentation (November 2026)

17 slides from Autonomix Medical's investor presentation, Nov 20, 2026

  1. Slide 1: Investor Presentation

    Slide 1: Investor Presentation

    NASDAQ: AMIX Investor Presentation November 2028

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    AUTONOMIX NASDAQ: AMIX Forward-Looking Statements [AL sutamentscontonoa heen o2ter then ststements of stone feet, lung statoments Fegurng ou uur esU of epertons end Manca poston. ou business stotog ae plans, ad our eboctvs for future operations Fe frwaréSooking stent: The words “bot,” “may” “wil” ex

  3. Slide 3: Unleashing the Power of Treatments

    Slide 3: Unleashing the Power of Treatments

    Unleashing the Power of Treatments Transforming minimally invasive transvascular technology to treat neurological diseases. Extensive IP Portfolio with 120+ Patents Issued and Pending High Sensitivity to Detect ang Differentiate Neural Signals, Enabling Real-Time, High Resolution Signal Capture Thro

  4. Slide 4: The Problem

    Slide 4: The Problem

    AUTONOMIX NASDAQ: AMIX The Problem Current Technologies Cannot Precisely Target and Treat Overactive Nerves. @ Current cardiac sensing technologies cannot detect low amplitude neuronal signals Senses (or maps) 100nV activity while neuronal signaling through the vessel wall is much lower, typically l

  5. Slide 5: Illuminating the Nervous System with Transvascular Precision-Guided Technology

    Slide 5: Illuminating the Nervous System with Transvascular Precision-Guided Technology

    QLAMIx AUTONOMIX |luminating the Nervous System with Transvascular Precision-Guided Technology >

  6. Slide 6: Enabling Sense, Treat and Verify

    Slide 6: Enabling Sense, Treat and Verify

    AuToNomix NASDAQ: AMIX Enabling Sense, Treat and Verify. Potential to Improve Patient 01 Through i ision-Guided Tr Sense (Identify) @ Treat (Ablate) @) Verify (Confirm) Overactive Nerves Target Nerves Treatment Precision Meping of Neural Advanced Ablation Catheter Immediate intre-Procedure ‘Acti to

  7. Slide 7: Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments

    Slide 7: Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments

    AUTONOMIX NASDAQ: AMIX Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments Summary + <5} High Sensitivity to Detect and Differentiate Neural Signal Strength ‘ASIC-Powered!' Proprietary Sensory Microchip Processes Signal at the Source + Signal Travels Only Millimeters ~ Preserving Sig

  8. Slide 8: PoC Study: First-in-Human Proof-of-Concept

    Slide 8: PoC Study: First-in-Human Proof-of-Concept

    PoC 1 Study: First-in- Human Proof-of-Concept Study in Pain Associated With Pancreatic Cancer PoC 1 Initial Phase and Demonstrated Statistically Number of Subje y o ry Endp. : Patients Clinical sit

  9. Slide 9: PoC Study: Met Efficacy and Safety Objectives

    Slide 9: PoC Study: Met Efficacy and Safety Objectives

    AUTONOMIX NASDAQ: AMIX PoC 1 Study: Met Efficacy and Safety Objectives 100% of patients (n=16) with femoral access responded to estment® Pain relief occurred ‘Long-lasting, durable pa 100% of responders Required Zero Opioid use at $-months post-procedure 77% improvement in global quality of health '

  10. Slide 10: Pain Reduction at 4-6 Weeks & Months

    Slide 10: Pain Reduction at 4-6 Weeks & Months

    Pain Reduction at 4-6 Weeks & 3 Months PANCREATIC CANCER PAIN PoC 1 STUDY: RESPONDING FEMORAL PATIENTS MEAN VAS SCORE OVER TIME ning Post-Procedure 7 Days Follow-Up fours) (+48 Hours)

  11. Slide 11: PoC Study: Subgroup Analysis Shows Pain Relief Across All Disease Stages

    Slide 11: PoC Study: Subgroup Analysis Shows Pain Relief Across All Disease Stages

    AUTONOMIX NASDAQ: AMIX PoC 1 Study: Subgroup Analysis Shows Pain Relief Observed Across All Disease Stages ‘Among ate-stag (Stage 4 cancer pti Across all disease stages, responding patients presenting with severe baseline pain Late-Stage Improvement tralia with rmna cdiassseepona Rapid Onset experie

  12. Slide 12: PoC Study: Follow-On Expansion Protocol

    Slide 12: PoC Study: Follow-On Expansion Protocol

    avronomix NASDAQ: AMIX PoC 2 Study: Follow-On Expansion Protocol of Proof-of-Concept Study Evaluation of pain management in additional visceral cancers, earlier stagelpancreatic cancer and procedural protocol of Autonomix Sensing & RF Ablation Catheters ent to Interventional Pancreatic in Management

  13. Slide 13: Path to Potential FDA Clearance

    Slide 13: Path to Potential FDA Clearance

    AUTONOMIX NASDAQ: AMIX Path to Potential FDA Clearance 2025 > 2028 IDE Clinical FDA De Novo Pocstudies |! Triaisinus P| Submission > FDA Clearance Revenue Generation Mo eg Ub Capital Expenditure Catheter Disposables del Annual Software License

  14. Slide 14: Proof-of-Concept in Lead Indication

    Slide 14: Proof-of-Concept in Lead Indication

    Proof-of-Concept in Lead Indication Opens Tot Me

  15. Slide 15: Proven Team with Multiple Successful Exits

    Slide 15: Proven Team with Multiple Successful Exits

    AUTONOMIX NASDAQ: AMIX Proven Team with Multiple Successful Exits

  16. Slide 16: Investment Highlights

    Slide 16: Investment Highlights

    Investment Highlights NASDAQ: AMIX Transforming the diagnosis and treatment of pain and diseases of the nervous system. AUTONOMIX Approximately $8.6! incash and 3,096,437 shares outstanding as of Unleashing the Power of November 20, 2026; cash expected to fund operations into, but not beyond, Nerve-

  17. Slide 17: Investor / Media Relations

    Slide 17: Investor / Media Relations

    7 ‘ONOMIX Investor / Media Relations soantors autonomix.com

Source: SEC EDGAR · 8-K filed Nov 20, 2026

More decks from Autonomix Medical, Inc.

All 7 Autonomix Medical decks